Tested low-dose radiation plus cadonilimab for nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This Phase 3 trial studies whether adding low-dose radiation to cadonilimab (an immune therapy) can improve outcomes for people newly diagnosed with a specific type and stage of nasopharyngeal cancer. If you’re eligible, it may offer a new treatment approach and helps researchers confirm whether it works best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a brand-new diagnosis of nasopharyngeal non-keratinizing cancer (a pathology test confirmed this type), stage WHO grade II or III
- You are 18 to 70 years old, and your overall health status is good (ECOG 0 to 1)
- Your cancer has no distant spread (no metastases), and it matches the study’s defined tumor/node stages (T4N1M0 or T1–4N2–3M0)
- You have not had any cancer treatment yet, including radiation, chemotherapy, or immunotherapy
- Your blood tests and organ function (liver, kidney, blood counts) are in safe ranges for treatment
- You can safely take the study medicines (no major uncontrolled heart problems, severe uncontrolled blood pressure, serious complications, or other major issues) and you can consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This Phase 3 trial tests whether adding a PD-1 immunotherapy (given with chemotherapy and radiation, and also after) can improve outcomes for people with high-risk nasopharyngeal cancer. It may help by strengthening the immune system’s attack on the cancer alongside standard treatment.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This trial tests whether a lower dose of radiation, with or without additional chemo-immunotherapy, works as well as the standard full-dose chemoradiation for people with advanced nasopharyngeal cancer who had a complete response after initial chemo-immunotherapy.
This trial tests whether a lower dose of radiation can safely treat stage III nasopharyngeal cancer if you have already responded well to initial chemotherapy plus immunotherapy (Camrelizumab). The goal is to reduce side effects while still controlling the cancer.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.